Huami, Tanger, and Editas Medicine have small market caps, but that only leaves them more room for multibagger returns.
News & Analysis: Editas Medicine
If CRISPR therapies pan out, the possibilities are vast.
They're risky, but these up-and-coming biotechs could be tremendous winners for investors willing to take on those risks.
The gene-editing specialist continues to move toward commercialization of its primary drug candidate.
Which of these struggling gene-editing biotechs is most likely to win over the long run?
Here's why Wall Street thinks these stocks could generate returns of 100% or more in the next 12 months.
The future of treating disease might be gene editing, and these five stocks have the most promising technologies.
The genome-editing leader just delivered an exciting quarterly update.
After another solid quarter of progress, the genome-editing company looks forward to a phase 1/2 study for its revolutionary CRISPR medicine.
EDIT earnings call for the period ending December 31, 2018.